Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:TXMD

TherapeuticsMD Q3 2026 Earnings Date & Estimates

TherapeuticsMD logo
$1.80 -0.05 (-2.70%)
As of 10/23/2026 04:00 PM Eastern

TherapeuticsMD is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from TherapeuticsMD in Q3 2026

TherapeuticsMD is expected to post earnings of -$6.1250 per share on revenue of $19.77 million. In the same quarter a year earlier TherapeuticsMD reported $0.0131 per share on revenue of $0.78 million. TherapeuticsMD last reported on August 11, 2026, posting $0.01 per share and beating the -$6.1250 consensus estimate. TherapeuticsMD has beaten the consensus EPS estimate in 3 of its last 4 quarters.

Consensus Estimates

Consensus EPS
-$6.1250
Expected Revenue
$19.77 million
Prior-Year EPS
$0.0131
Prior-Year Revenue
$0.78 million
Expected EPS Growth
-46,738.7%
Expected Revenue Growth
+2,421.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.01 (Beat by +$6.1350)
Last Quarter Revenue
$0.87 million
EPS Beat Rate
3 of last 4 quarters

Prepare for the Q3 2026 Call

TherapeuticsMD Q3 2026 Earnings FAQ

TherapeuticsMD (NASDAQ:TXMD) is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

TherapeuticsMD's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect TherapeuticsMD to post earnings of -$6.1250 per share for Q3 2026.

The consensus revenue estimate for TherapeuticsMD is $19.77 million for Q3 2026.

TherapeuticsMD Earnings Headlines

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains
June 5, 2026  |  marketwatch.comhttps://www.marketwatch.com/data-news/therapeuticsmd-inc-stock-underperforms-thursday-when-compared-to-competitors-despite-daily-gains-e98194d4-63e529e0f496
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives
May 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/therapeuticsmd-reports-quarterly-profit-evaluates-strategic-alternatives?utm_source=marketbeat.com&utm_medium=referral
Your book is inside
Blane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn 100 Into 1000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.tc pixel
 |  TradeWins (Ad)
TherapeuticsMD Announces First Quarter 2026 Financial Results
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512202804/en/therapeuticsmd-announces-first-quarter-2026-financial-results/
TherapeuticsMD Inc. stock outperforms competitors on strong trading day
April 6, 2026  |  marketwatch.comhttps://www.marketwatch.com/data-news/therapeuticsmd-inc-stock-outperforms-competitors-on-strong-trading-day-040b2196-45a687e58918
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy
April 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TXMD/pressreleases/1078704/therapeuticsmd-narrows-2025-loss-advances-royalty-strategy/
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) was a pharmaceutical company focused on women’s health. The company developed and commercialized prescription products intended to address reproductive health, contraception, and menopause-related conditions.

Its portfolio included Annovera, a reusable vaginal contraceptive system; Imvexxy, a vaginal insert for the treatment of moderate-to-severe vulvar and vaginal atrophy associated with menopause; and Bijuva, an oral hormone therapy for menopausal symptoms. TherapeuticsMD also operated vitaCare Prescription Services, a platform designed to support prescription access, fulfillment, and patient services.

TherapeuticsMD was headquartered in Boca Raton, Florida, and its products were marketed primarily in the United States. The company was acquired by affiliates of EW Healthcare Partners in 2023 and subsequently became a privately held company; its common stock was no longer publicly traded on Nasdaq.

View TherapeuticsMD Profile
Earnings Tools